Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermittent versus continuous androgen suppression for prostatic cancer.

P D Conti, A N Atallah, H Arruda

    The Cochrane Database of Systematic Reviews
    |October 19, 2007
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Prophylactic anticoagulants for people hospitalized with COVID-19: systematic review.

    The British journal of surgery·2021
    Same author

    Reply by Authors.

    The Journal of urology·2020
    Same author

    Minoxidil for patchy alopecia areata: systematic review and meta-analysis.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2019
    Same author

    Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial.

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2014
    Same author

    Treatment for agenesis of maxillary lateral incisors: a systematic review.

    Orthodontics & craniofacial research·2013
    Same author

    Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis.

    Prostate cancer and prostatic diseases·2011
    Same journal

    Interventions to prevent or cease electronic cigarette use in children and adolescents.

    The Cochrane database of systematic reviews·2026
    Same journal

    Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

    The Cochrane database of systematic reviews·2026
    Same journal

    Interventions for smoking cessation in inpatient psychiatry settings.

    The Cochrane database of systematic reviews·2026
    Same journal

    Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

    The Cochrane database of systematic reviews·2026
    Same journal

    Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

    The Cochrane database of systematic reviews·2026
    Same journal

    Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

    The Cochrane database of systematic reviews·2026
    See all related articles

    Intermittent androgen suppression (IAS) shows similar effectiveness to continuous androgen suppression (CAS) for prostate cancer, with potentially fewer adverse events like impotence. However, data are limited by small sample sizes and short study durations.

    Area of Science:

    • Urology
    • Oncology
    • Clinical Trials

    Background:

    • Prostate cancer is a leading cause of cancer death in men.
    • Androgen suppression therapy (AST) is a standard treatment for advanced prostate cancer.
    • The use of AST for early-stage disease is increasing despite limited evidence.

    Purpose of the Study:

    • To evaluate the effectiveness and safety of intermittent androgen suppression (IAS) compared to continuous androgen suppression (CAS) in prostate cancer treatment.
    • To analyze outcomes including biochemical progression and adverse events.

    Main Methods:

    • Systematic review of randomized or quasi-randomized controlled trials.
    • Searched databases: Cochrane Central Register of Controlled Trials, EMBASE, and LILACS.
    • Two reviewers assessed study quality and extracted data.

    Related Experiment Videos

    Main Results:

    • Five trials with 1382 patients were included, all focusing on advanced prostate cancer.
    • No significant difference in biochemical progression for Gleason scores 4-10, but favored IAS for Gleason > 6.
    • IAS showed a significant reduction in impotence compared to CAS, with no difference in other adverse events.

    Conclusions:

    • Limited data from small, short-duration trials restrict definitive conclusions on IAS vs. CAS effectiveness for survival or disease progression.
    • IAS may offer a slight reduction in adverse events, particularly impotence.
    • IAS appears as effective as CAS for potency, with superiority noted during treatment intervals.